Log In
Print
BCIQ
Print
Print this Print this
 

varlilumab (CDX-1127)

  Manage Alerts
Collapse Summary General Information
Company Celldex Therapeutics Inc.
DescriptionHuman mAb targeting CD27
Molecular Target CD27
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$5.0M

$5.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today